Further evaluation is warranted." Phase 1 Study Overview: BOT/BAL in Treatment-Refractory Hepatocellular Carcinoma (NCT03860272) The HCC cohort enrolled 19 patients (18 evaluable for efficacy ...

Agenus Inc. , a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in ...

The report includes clinical and nonclinical drug profiles, therapeutic assessments, and details on emerging drugs like Ricolinostat and CKD 506. Ideal for stakeholders in oncology and therapeutic R&D ...

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient po ...

Industry Giants Gilead Sciences, Bristol Myers Squibb, AbbVie, and Merck & Co. Lead the CompetitionDublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Liver Disease Treatments Market" report has been added ...

Background: Hepatocellular carcinoma (HCC) accounts for 75-85% of primary liver ... Despite these limitations, our analysis provides a comprehensive overview of the current state of the field. This ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...

Immunotherapy is the use of medicines that help a person’s own immune system find and destroy cancer cells. It can be used to treat some people with liver cancer. An important part of the immune ...

It is a leading cause of liver cancer, responsible for 50%-80% of hepatocellular carcinoma cases globally. 1 Chronic HBV infection leads to the integration of HBV DNA into the host genome, resulting ...

Solute carrier family 25 member 19 (SLC25A19) is a transporter protein of thiamine pyrophosphate across cellular membranes, which is needed as a cofactor for multiple metabolic enzymes and is ...